 Skye Bioscience inc OTCQB:SKYE announced that the peer-reviewed journal International Journal of Pharmaceutics has published preclinical data demonstrating stronger and longer-lasting reduction of intraocular pressure IOP when Skyes proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940. The pharmaceutical company, which is developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases, said a first in-human study of the formulation is planned to start this quarter. 